Santé - HealthTech

Braintale mesure le cerveau de façon universelle pour permettre la bonne prise en charge clinique et améliorer l’efficacité des études cliniques en neurologie et réanimation.

Créé le 11 juillet 2018


Niveau de maturité

  • Idéation

  • R&D

  • Minimum viable product

  • 1er client / 1ers utilisateurs

  • Commercialisation


Illuminating brain diseases

Braintale opens a new era to offer clinically validated, standardized and unique set of solutions to provide better care for brain injured patients.

BrainTale is a medtech spin-off from Paris Hospital specialist in white matter, a long-underestimated area of ​​interest in neurosciences.

The company offers its users – doctors, university hospitals and partners in the health sector – a platform of unique digital biomarkers, which can be employed in daily practice. Biomarkers are derived from magnetic resonance imaging, non-invasive measurements providing sensitive and reliable assessments of white matter alterations. Objective: establish a new standard for measuring the brain that is both relevant and useful for patients, doctors, researchers, and commercial players developing treatments.

Supporting clinical decision-making, these data are decisive for neurology and intensive care management using clinically validated predictive solutions.

BrainTale allows the identification of patients at risk, early diagnosis, follow-up of disease progression and effectiveness of treatments in neurology, in particular for demyelinating diseases (such as multiple sclerosis), neurodegenerative diseases (such as Alzheimer’s disease) or trauma brain injury.

Site web :

Porteurs de projets

  • Julie Rachline